KIT and gastrointestinal stromal tumor: The gain-of-function of KIT mutations resulting in the constitutive activation of the protein, genomic context and alternative signaling pathways, also largely affect the efficacy of IM, as well as sunitinib, and regrifinib and ripritinib, which mostly due to the different transcriptional programs observed in GIST with various genotypes that influenced the protein active structures, dimerization affinity, and cellular localization [35].